Top

Published in:

Open Access 01-12-2014 | Review

Macrophages in solid organ transplantation

Authors: Xinguo Jiang, Wen Tian, Yon K Sung, Jin Qian, Mark R Nicolls

Published in: Vascular Cell | Issue 1/2014

Abstract

Macrophages are highly plastic hematopoietic cells with diversified functions related to their anatomic location and differentiation states. A number of recent studies have examined the role of macrophages in solid organ transplantation. These studies show that macrophages can induce allograft injury but, conversely, can also promote tissue repair in ischemia-reperfusion injury and acute rejection. Therapeutic strategies that target macrophages to improve outcomes in solid organ transplant recipients are being examined in preclinical and clinical models. In this review, we discuss the role of macrophages in different types of injury and rejection, with a focus on macrophage-mediated tissue injury, specifically vascular injury, repair and remodeling. We also discuss emerging macrophage-centered therapeutic opportunities in solid organ transplantation.

Available only for authorised users

Metchnikoff É: Immunity in Infective Diseases. 1905, London: Cambridge University Press

Wynn TA, Chawla A, Pollard JW: Macrophage biology in development, homeostasis and disease. Nature. 2013, 496 (7446): 445-455. 10.1038/nature12034.PubMedCentralPubMed

Van Dyken SJ, Locksley RM: Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. 2013, 31: 317-343. 10.1146/annurev-immunol-032712-095906.PubMedCentralPubMed

Lawrence T, Natoli G: Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011, 11 (11): 750-761. 10.1038/nri3088.PubMed

Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, MacDonald AS, Allen JE: Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science. 2011, 332 (6035): 1284-1288. 10.1126/science.1204351.PubMedCentralPubMed

Murray PJ, Wynn TA: Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011, 11 (11): 723-737. 10.1038/nri3073.PubMedCentralPubMed

Stein M, Keshav S, Harris N, Gordon S: Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992, 176 (1): 287-292. 10.1084/jem.176.1.287.PubMed

Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 2003, 3 (1): 23-35. 10.1038/nri978.PubMed

Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32 (5): 593-604. 10.1016/j.immuni.2010.05.007.PubMed

10.

Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008, 8 (12): 958-969. 10.1038/nri2448.PubMedCentralPubMed

11.

Broichhausen C, Riquelme P, Geissler EK, Hutchinson JA: Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation. Curr Opin Organ Transplant. 2012, 17 (4): 332-342.PubMed

12.

Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman TC, Ulas T, Schultze JL: Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014, 40 (2): 274-288. 10.1016/j.immuni.2014.01.006.PubMedCentralPubMed

13.

Strom TB, Tilney NL, Carpenter CB, Busch GJ: Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med. 1975, 292 (24): 1257-1263. 10.1056/NEJM197506122922402.PubMed

14.

von Willebrand E, Hayry P: Composition and in vitro cytotoxicity of cellular infiltrates in rejecting human kidney allografts. Cell Immunol. 1978, 41 (2): 358-372. 10.1016/0008-8749(78)90233-2.PubMed

15.

Mitchell RN: Graft vascular disease: immune response meets the vessel wall. Annu Rev Pathol. 2009, 4: 19-47. 10.1146/annurev.pathol.3.121806.151449.PubMed

16.

Magil AB: Monocytes/macrophages in renal allograft rejection. Transplant Rev (Orlando). 2009, 23 (4): 199-208. 10.1016/j.trre.2009.06.005.

17.

Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ: The role of macrophages in allograft rejection. Transplantation. 2005, 80 (12): 1641-1647. 10.1097/01.tp.0000173903.26886.20.PubMed

18.

Mannon RB: Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders?. Curr Opin Organ Transplant. 2012, 17 (1): 20-25. 10.1097/MOT.0b013e32834ee5b6.PubMedCentralPubMed

19.

Jiang X, Khan MA, Tian W, Beilke J, Natarajan R, Kosek J, Yoder MC, Semenza GL, Nicolls MR: Adenovirus-mediated HIF-1alpha gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest. 2011, 121 (6): 2336-2349. 10.1172/JCI46192.PubMedCentralPubMed

20.

Weber DJ, Wilkes DS: The role of autoimmunity in obliterative bronchiolitis after lung transplantation. Am J Physiol Lung Cell Mol Physiol. 2013, 304 (5): L307-L311. 10.1152/ajplung.00378.2012.PubMedCentralPubMed

21.

McKay D, Jameson J: Kidney transplantation and the ageing immune system. Nat Rev Nephrol. 2012, 8 (12): 700-708.PubMed

22.

Eltzschig HK, Eckle T: Ischemia and reperfusion–from mechanism to translation. Nat Med. 2011, 17 (11): 1391-1401. 10.1038/nm.2507.PubMed

23.

Eltzschig HK, Carmeliet P: Hypoxia and inflammation. N Engl J Med. 2011, 364 (7): 656-665. 10.1056/NEJMra0910283.PubMedCentralPubMed

24.

Hotchkiss RS, Strasser A, McDunn JE, Swanson PE: Cell death. N Engl J Med. 2009, 361 (16): 1570-1583. 10.1056/NEJMra0901217.PubMedCentralPubMed

25.

Chen GY, Nunez G: Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010, 10 (12): 826-837. 10.1038/nri2873.PubMedCentralPubMed

26.

Martins PN, Chandraker A, Tullius SG: Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment. Trans Int Official J Eur Soc Org Trans. 2006, 19 (5): 351-359.

27.

Jo SK, Sung SA, Cho WY, Go KJ, Kim HK: Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol Dial Transplant. 2006, 21 (5): 1231-1239. 10.1093/ndt/gfk047.PubMed

28.

Ke B, Shen XD, Zhang Y, Ji H, Gao F, Yue S, Kamo N, Zhai Y, Yamamoto M, Busuttil RW, Kupiec-Weglinski JW: Keap1-Nrf2 Complex in Ischemia-Induced Hepatocellular Damage of Mouse Liver Transplants. J Hepatol. 2013, 59 (6): 1200-7. 10.1016/j.jhep.2013.07.016.PubMedCentralPubMed

29.

Liu Q, Rehman H, Shi Y, Krishnasamy Y, Lemasters JJ, Smith CD, Zhong Z: Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS One. 2012, 7 (7): e41834-10.1371/journal.pone.0041834.PubMedCentralPubMed

30.

Tuuminen R, Syrjala S, Krebs R, Arnaudova R, Rouvinen E, Nykanen AI, Lemstrom KB: Combined donor simvastatin and methylprednisolone treatment prevents ischemia-reperfusion injury in rat cardiac allografts through vasculoprotection and immunomodulation. Transplantation. 2013, 95 (9): 1084-1091. 10.1097/TP.0b013e3182881b61.PubMed

31.

Zhao M, Fernandez LG, Doctor A, Sharma AK, Zarbock A, Tribble CG, Kron IL, Laubach VE: Alveolar macrophage activation is a key initiation signal for acute lung ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol. 2006, 291 (5): L1018-1026. 10.1152/ajplung.00086.2006.PubMed

32.

Kohno M, Watanabe M, Goto T, Kamiyama I, Ohtsuka T, Tasaka S, Sawafuji M: Attenuation of Lung Ischemia-Reperfusion Injury by Rho-Associated Kinase Inhibition in a Rat Model of Lung Transplantation. Ann Thorac Cardiovasc Surg. 2013, In Press

33.

Moreau A, Varey E, Anegon I, Cuturi MC: Effector mechanisms of rejection. Cold Spring Harb Perspect Med. 2013, 3: a015461-10.1101/cshperspect.a015461.PubMedCentralPubMed

34.

McCoy CE, O'Neill LA: The role of toll-like receptors in macrophages. Front Biosci. 2008, 13: 62-70. 10.2741/2660.PubMed

35.

Bell MT, Puskas F, Agoston VA, Cleveland JC, Freeman KA, Gamboni F, Herson PS, Meng X, Smith PD, Weyant MJ, Fullerton DA, Reece TB: Toll-like receptor 4-dependent microglial activation mediates spinal cord ischemia-reperfusion injury. Circulation. 2013, 128 (26 Suppl 1): S152-S156.PubMed

36.

Zhu H, Li J, Wang S, Liu K, Wang L, Huang L: Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model. Transplantation. 2013, 95 (12): 1448-1454. 10.1097/TP.0b013e318293b7e1.PubMed

37.

Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I, Sekiya T, Ooboshi H, Kitazono T, Yanagawa T, Ishii T, Takahashi H, Mori S, Nishibori M, Kuroda K, Akira S, Miyake K, Yoshimura A: Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med. 2012, 18 (6): 911-917. 10.1038/nm.2749.PubMed

38.

Lin SL, Li B, Rao S, Yeo EJ, Hudson TE, Nowlin BT, Pei H, Chen L, Zheng JJ, Carroll TJ, Pollard JW, McMahon AP, Lang RA, Duffield JS: Macrophage Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci USA. 2010, 107 (9): 4194-4199. 10.1073/pnas.0912228107.PubMedCentralPubMed

39.

Menke J, Iwata Y, Rabacal WA, Basu R, Yeung YG, Humphreys BD, Wada T, Schwarting A, Stanley ER, Kelley VR: CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest. 2009, 119 (8): 2330-2342. 10.1172/JCI39087.PubMedCentralPubMed

40.

Paulus P, Holfeld J, Urbschat A, Mutlak H, Ockelmann PA, Tacke S, Zacharowski K, Reissig C, Stay D, Scheller B: Prednisolone as preservation additive prevents from ischemia reperfusion injury in a rat model of orthotopic lung transplantation. PLoS One. 2013, 8 (8): e73298-10.1371/journal.pone.0073298.PubMedCentralPubMed

41.

Li W, Zhang Q, Wang M, Wu H, Mao F, Zhang B, Ji R, Gao S, Sun Z, Zhu W, Qian H, Chen Y, Xu W: Macrophages are involved in the protective role of human umbilical cord-derived stromal cells in renal ischemia-reperfusion injury. Stem Cell Res. 2013, 10 (3): 405-416. 10.1016/j.scr.2013.01.005.PubMed

42.

Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, Ruhrberg C, Cantley LG: Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011, 22 (2): 317-326. 10.1681/ASN.2009060615.PubMedCentralPubMed

43.

Ohkubo H, Ito Y, Minamino T, Mishima T, Hirata M, Hosono K, Shibuya M, Yokomizo T, Shimizu T, Watanabe M, Majima M: Leukotriene B4 type-1 receptor signaling promotes liver repair after hepatic ischemia/reperfusion injury through the enhancement of macrophage recruitment. FASEB J. 2013, 27 (8): 3132-3143. 10.1096/fj.13-227421.PubMed

44.

Ponticelli C: The mechanisms of acute transplant rejection revisited. J Nephrol. 2012, 25 (2): 150-158. 10.5301/jn.5000048.PubMed

45.

Drachenberg CB, Papadimitriou JC: Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis. Transplantation. 2013, 95 (9): 1073-1083. 10.1097/TP.0b013e31827e6b45.PubMed

46.

Girlanda R, Kleiner DE, Duan Z, Ford EA, Wright EC, Mannon RB, Kirk AD: Monocyte infiltration and kidney allograft dysfunction during acute rejection. Am J Trans Official J Am Soc Trans Am Soc Trans Surg. 2008, 8 (3): 600-607. 10.1111/j.1600-6143.2007.02109.x.

47.

Jose MD, Ikezumi Y, van Rooijen N, Atkins RC, Chadban SJ: Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation. 2003, 76 (7): 1015-1022. 10.1097/01.TP.0000083507.67995.13.PubMed

48.

Poosti F, Yazdani S, Dolman ME, Kok RJ, Chen C, Ding G, Lacombe M, Prakash J, van den Born J, Hillebrands JL, van Goor H, de Borst MH: Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. Eur J Pharmacol. 2012, 694 (1–3): 111-119.PubMed

49.

Fishbein GA, Fishbein MC: Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Human Immunol. 2012, 73 (12): 1213-1217. 10.1016/j.humimm.2012.07.011.

50.

Fedrigo M, Feltrin G, Poli F, Frigo AC, Benazzi E, Gambino A, Tona F, Caforio AL, Castellani C, Toscano G, Gerosa G, Thiene G, Angelini A: Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection. J Heart Lung Transplant Official Pub Int Soc Heart Transplantat. 2013, 32 (4): 404-409. 10.1016/j.healun.2012.12.017.

51.

Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA: CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol. 2002, 3 (2): 143-150. 10.1038/ni749.PubMed

52.

Valenzuela NM, Hong L, Shen XD, Gao F, Young SH, Rozengurt E, Kupiec-Weglinski JW, Fishbein MC, Reed EF: Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant Official J Am Soc Transplant Am Soc Transplant Surg. 2013, 13 (2): 299-311. 10.1111/ajt.12016.

53.

Grandaliano G, Gesualdo L, Ranieri E, Monno R, Stallone G, Schena FP: Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation. 1997, 63 (3): 414-420. 10.1097/00007890-199702150-00015.PubMed

54.

Lan HY, Yang N, Brown FG, Isbel NM, Nikolic-Paterson DJ, Mu W, Metz CN, Bacher M, Atkins RC, Bucala R: Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation. 1998, 66 (11): 1465-1471. 10.1097/00007890-199812150-00009.PubMed

55.

Le Meur Y, Jose MD, Mu W, Atkins RC, Chadban SJ: Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection. Transplantation. 2002, 73 (8): 1318-1324. 10.1097/00007890-200204270-00022.PubMed

56.

Jose MD, Le Meur Y, Atkins RC, Chadban SJ: Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am J Transplant. 2003, 3 (3): 294-300. 10.1034/j.1600-6143.2003.00068.x.PubMed

57.

Hoffmann U, Bergler T, Segerer S, Rummele P, Kruger B, Banas MC, Reinhold S, Banas B, Kramer BK: Impact of chemokine receptor CX3CR1 in human renal allograft rejection. Transplant Immunol. 2010, 23 (4): 204-208. 10.1016/j.trim.2010.06.006.

58.

Kakuta Y, Okumi M, Miyagawa S, Tsutahara K, Abe T, Yazawa K, Matsunami K, Otsuka H, Takahara S, Nonomura N: Blocking of CCR5 and CXCR3 suppresses the infiltration of macrophages in acute renal allograft rejection. Transplantation. 2012, 93 (1): 24-31. 10.1097/TP.0b013e31823aa585.PubMed

59.

Schroder C, Pierson RN, Nguyen BN, Kawka DW, Peterson LB, Wu G, Zhang T, Springer MS, Siciliano SJ, Iliff S, Ayala JM, Lu M, Mudgett JS, Lyons K, Mills SG, Miller GG, Singer II, Azimzadeh AM, DeMartino JA: CCR5 blockade modulates inflammation and alloimmunity in primates. J Immunol. 2007, 179 (4): 2289-2299.PubMed

60.

Azzawi M, Hasleton PS, Geraghty PJ, Yonan N, Krysiak P, El-Gammal A, Deiraniya AK, Hutchinson IV: RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45RO T-lymphocytes and macrophages. J Heart Lung Transplant Official Pub Int Soc Heart Transplant. 1998, 17 (9): 881-887.

61.

Kajiwara I, Kawamura K, Takebayashi S: An analysis of monocyte/macrophage subsets and granulocyte-macrophage colony-stimulating factor expression in renal allograft biopsies. Nephron. 1996, 73 (4): 536-543.PubMed

62.

Worrall NK, Lazenby WD, Misko TP, Lin TS, Rodi CP, Manning PT, Tilton RG, Williamson JR, Ferguson TB: Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med. 1995, 181 (1): 63-70. 10.1084/jem.181.1.63.PubMed

63.

Ioannidis I, Hellinger A, Dehmlow C, Rauen U, Erhard J, Eigler FW, De Groot H: Evidence for increased nitric oxide production after liver transplantation in humans. Transplantation. 1995, 59 (9): 1293-1297. 10.1097/00007890-199505000-00012.PubMed

64.

Roza AM, Cooper M, Pieper G, Hilton G, Dembny K, Lai CS, Lindholm P, Komorowski R, Felix C, Johnson C, Adams M: NOX 100, a nitric oxide scavenger, enhances cardiac allograft survival and promotes long-term graft acceptance. Transplantation. 2000, 69 (2): 227-231. 10.1097/00007890-200001270-00006.PubMed

65.

Holan V, Krulova M, Zajicova A, Pindjakova J: Nitric oxide as a regulatory and effector molecule in the immune system. Mol Immunol. 2002, 38 (12–13): 989-995.PubMed

66.

Takeiri M, Tachibana M, Kaneda A, Ito A, Ishikawa Y, Nishiyama S, Goto R, Yamashita K, Shibasaki S, Hirokata G, Ozaki M, Todo S, Umezawa K: Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone. Inflamm Res. 2011, 60 (9): 879-888. 10.1007/s00011-011-0348-z.PubMed

67.

Kipari T, Cailhier JF, Ferenbach D, Watson S, Houlberg K, Walbaum D, Clay S, Savill J, Hughes J: Nitric oxide is an important mediator of renal tubular epithelial cell death in vitro and in murine experimental hydronephrosis. Am J Pathol. 2006, 169 (2): 388-399. 10.2353/ajpath.2006.050964.PubMedCentralPubMed

68.

Chadban SJ, Wu H, Hughes J: Macrophages and kidney transplantation. Semin Nephrol. 2010, 30 (3): 278-289. 10.1016/j.semnephrol.2010.03.009.PubMed

69.

Babu AN, Murakawa T, Thurman JM, Miller EJ, Henson PM, Zamora MR, Voelkel NF, Nicolls MR: Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest. 2007, 117 (12): 3774-3785. 10.1172/JCI32311.PubMedCentralPubMed

70.

Khan MA, Jiang X, Dhillon G, Beilke J, Holers VM, Atkinson C, Tomlinson S, Nicolls MR: CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011, 109 (11): 1290-1301. 10.1161/CIRCRESAHA.111.250167.PubMedCentralPubMed

71.

Bishop GA, Waugh JA, Landers DV, Krensky AM, Hall BM: Microvascular destruction in renal transplant rejection. Transplantation. 1989, 48 (3): 408-414. 10.1097/00007890-198909000-00011.PubMed

72.

Matsumoto Y, McCaughan GW, Painter DM, Bishop GA: Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation. 1993, 56 (1): 69-75. 10.1097/00007890-199307000-00012.PubMed

73.

Luckraz H, Goddard M, McNeil K, Atkinson C, Charman SC, Stewart S, Wallwork J: Microvascular changes in small airways predispose to obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant Official Pub Int Soc Heart Transplant. 2004, 23 (5): 527-531.

74.

Luckraz H, Goddard M, McNeil K, Atkinson C, Sharples LD, Wallwork J: Is obliterative bronchiolitis in lung transplantation associated with microvascular damage to small airways?. Ann Thorac Surg. 2006, 82 (4): 1212-1218. 10.1016/j.athoracsur.2006.03.070.PubMed

75.

Lobov IB, Rao S, Carroll TJ, Vallance JE, Ito M, Ondr JK, Kurup S, Glass DA, Patel MS, Shu W, Morrisey EE, McMahon AP, Karsenty G, Lang RA: WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature. 2005, 437 (7057): 417-421. 10.1038/nature03928.PubMedCentralPubMed

76.

Adair A, Mitchell DR, Kipari T, Qi F, Bellamy CO, Robertson F, Hughes J, Marson LP: Peritubular capillary rarefaction and lymphangiogenesis in chronic allograft failure. Transplantation. 2007, 83 (12): 1542-1550. 10.1097/01.tp.0000266689.93615.cd.PubMed

77.

Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L, Rabinovitch M, Zamanian RT, Inayathullah M, Fridlib M, Rajadas J, Peters-Golden M, Voelkel NF, Nicolls MR: Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med. 2013, 5 (200): 200ra117-PubMedCentralPubMed

78.

De Palma M, Lewis CE: Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013, 23 (3): 277-286. 10.1016/j.ccr.2013.02.013.PubMed

79.

Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE: TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest. 2011, 121 (5): 1969-1973. 10.1172/JCI44562.PubMedCentralPubMed

80.

Nucera S, Biziato D, De Palma M: The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. Int J Dev Biol. 2011, 55 (4–5): 495-503.PubMed

81.

Patel AS, Smith A, Nucera S, Biziato D, Saha P, Attia RQ, Humphries J, Mattock K, Grover SP, Lyons OT, Guidotti LG, Siow R, Ivetic A, Egginton S, Waltham M, Naldini L, De Palma M, Modarai B: TIE2-expressing monocytes/macrophages regulate revascularization of the ischemic limb. EMBO Mol Med. 2013, 5 (6): 858-869. 10.1002/emmm.201302752.PubMedCentralPubMed

82.

Jiang X: Harnessing the immune system for the treatment of breast cancer. J Zhejiang Univ Sci B. 2014, 15 (1): 1-15.PubMedCentralPubMed

83.

Jiang X, Hsu JL, Tian W, Yuan K, Olcholski M, de Jesus PV, Semenza GL, Nicolls MR: Tie2-dependent VHL knockdown promotes airway microvascular regeneration and attenuates invasive growth of Aspergillus fumigatus. J Mol Med (Berl). 2013, 91 (9): 1081-93. 10.1007/s00109-013-1063-8.

84.

Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C: Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010, 10 (4): 482-496. 10.1016/j.coph.2010.04.001.PubMed

85.

Hume DA, MacDonald KP: Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012, 119 (8): 1810-1820. 10.1182/blood-2011-09-379214.PubMed

86.

Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ: Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol. 2002, 169 (5): 2253-2263.PubMed

87.

Rickard AJ, Young MJ: Corticosteroid receptors, macrophages and cardiovascular disease. J Mole Endocrinol. 2009, 42 (6): 449-459. 10.1677/JME-08-0144.

88.

Kalinski P: Regulation of immune responses by prostaglandin E2. J Immunol. 2012, 188 (1): 21-28. 10.4049/jimmunol.1101029.PubMedCentralPubMed

89.

Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH: Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol. 2005, 175 (9): 5601-5605.PubMed

90.

Dillon S, Agrawal S, Banerjee K, Letterio J, Denning TL, Oswald-Richter K, Kasprowicz DJ, Kellar K, Pare J, van Dyke T, Ziegler S, Unutmaz D, Pulendran B: Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest. 2006, 116 (4): 916-928. 10.1172/JCI27203.PubMedCentralPubMed

91.

Hutchinson JA, Riquelme P, Geissler EK, Fandrich F: Human regulatory macrophages. Methods Mole Biol. 2011, 677: 181-192.

92.

Hutchinson JA, Riquelme P, Sawitzki B, Tomiuk S, Miqueu P, Zuhayra M, Oberg HH, Pascher A, Lutzen U, Janssen U, Broichhausen C, Renders L, Thaiss F, Scheuermann E, Henze E, Volk HD, Chatenoud L, Lechler RI, Wood KJ, Kabelitz D, Schlitt HJ, Geissler EK, Fändrich F: Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol. 2011, 187 (5): 2072-2078. 10.4049/jimmunol.1100762.PubMed

93.

Riquelme P, Tomiuk S, Kammler A, Fandrich F, Schlitt HJ, Geissler EK, Hutchinson JA: IFN-gamma-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mole Therapy J Am Soc Gene Therapy. 2013, 21 (2): 409-422. 10.1038/mt.2012.168.

94.

Mitchell RN: Learning from rejection: What transplantation teaches us about (other) vascular pathologies. J Autoimmun. 2013, 45: 80-89.PubMed

95.

Libby P, Tanaka H: The pathogenesis of coronary arteriosclerosis ("chronic rejection") in transplanted hearts. Clin Transplant. 1994, 8 (3 Pt 2): 313-318.PubMed

96.

Russell ME, Wallace AF, Hancock WW, Sayegh MH, Adams DH, Sibinga NE, Wyner LR, Karnovsky MJ: Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection. Transplantation. 1995, 59 (4): 572-578. 10.1097/00007890-199559040-00023.PubMed

97.

Hutchinson IV: Cardiac allograft vasculopathy--the cellular attack. Z Kardiol. 2000, 89 (Suppl 9): X/16-X/20.

98.

Libby P, Pober JS: Chronic rejection. Immunity. 2001, 14 (4): 387-397. 10.1016/S1074-7613(01)00119-4.PubMed

99.

Huibers M, De Jonge N, Van Kuik J, Koning ES, Van Wichen D, Dullens H, Schipper M, De Weger R: Intimal fibrosis in human cardiac allograft vasculopathy. Transplant Immunol. 2011, 25 (2–3): 124-132.

100.

Kitchens WH, Chase CM, Uehara S, Cornell LD, Colvin RB, Russell PS, Madsen JC: Macrophage depletion suppresses cardiac allograft vasculopathy in mice. Am J Transplant Official J Am Soc Transplant Am Soc Transplant Surg. 2007, 7 (12): 2675-2682. 10.1111/j.1600-6143.2007.01997.x.

101.

Azuma H, Nadeau KC, Ishibashi M, Tilney NL: Prevention of functional, structural, and molecular changes of chronic rejection of rat renal allografts by a specific macrophage inhibitor. Transplantation. 1995, 60 (12): 1577-1582. 10.1097/00007890-199560120-00034.PubMed

102.

Loupy A, Cazes A, Guillemain R, Amrein C, Hedjoudje A, Tible M, Pezzella V, Fabiani JN, Suberbielle C, Nochy D, Hill GS, Empana JP, Jouven X, Bruneval P, Duong Van Huyen JP: Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant Official J Am Soc Transplant Am Soc Transplant Surg. 2011, 11 (7): 1478-1487. 10.1111/j.1600-6143.2011.03563.x.

103.

Lourenco-Filho DD, Maranhao RC, Mendez-Contreras CA, Tavares ER, Freitas FR, Stolf NA: An artificial nanoemulsion carrying paclitaxel decreases the transplant heart vascular disease: a study in a rabbit graft model. J Thorac Cardiovasc Surg. 2011, 141 (6): 1522-1528. 10.1016/j.jtcvs.2010.08.032.PubMed

104.

Waanders F, Rienstra H, Boer MW, Zandvoort A, Rozing J, Navis G, van Goor H, Hillebrands JL: Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. Am J Physiol Renal Physiol. 2009, 296 (5): F1072-1079. 10.1152/ajprenal.90643.2008.PubMed

105.

Suzuki J, Cole SE, Batirel S, Kosuge H, Shimizu K, Isobe M, Libby P, Mitchell RN: Tumor necrosis factor receptor -1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant Official J Am Soc Transplant Am Soc Transplant Surg. 2003, 3 (8): 968-976. 10.1034/j.1600-6143.2003.00164.x.

106.

Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P: Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest. 1997, 100 (3): 550-557. 10.1172/JCI119564.PubMedCentralPubMed

107.

Tellides G, Pober JS: Interferon-gamma axis in graft arteriosclerosis. Circ Res. 2007, 100 (5): 622-632. 10.1161/01.RES.0000258861.72279.29.PubMed

108.

Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U: Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002, 195 (2): 245-257. 10.1084/jem.20011022.PubMedCentralPubMed

109.

Hillebrands JL, Klatter FA, van den Hurk BM, Popa ER, Nieuwenhuis P, Rozing J: Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest. 2001, 107 (11): 1411-1422. 10.1172/JCI10233.PubMedCentralPubMed

110.

Glaser R, Lu MM, Narula N, Epstein JA: Smooth muscle cells, but not myocytes, of host origin in transplanted human hearts. Circulation. 2002, 106 (1): 17-19. 10.1161/01.CIR.0000021923.58307.8F.PubMed

111.

Goldberg SH, van der Meer P, Hesselgesser J, Jaffer S, Kolson DL, Albright AV, Gonzalez-Scarano F, Lavi E: CXCR3 expression in human central nervous system diseases. Neuropathol App Neurobiol. 2001, 27 (2): 127-138. 10.1046/j.1365-2990.2001.00312.x.

112.

Sakihama H, Masunaga T, Yamashita K, Hashimoto T, Inobe M, Todo S, Uede T: Stromal cell-derived factor-1 and CXCR4 interaction is critical for development of transplant arteriosclerosis. Circulation. 2004, 110 (18): 2924-2930. 10.1161/01.CIR.0000146890.93172.6C.PubMed

113.

Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, Charo IF, Mach F: Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation. 2005, 112 (6): 870-878. 10.1161/CIRCULATIONAHA.104.520718.PubMed

114.

Kodali RB, Kim WJ, Galaria II, Miller C, Schecter AD, Lira SA, Taubman MB: CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 2004, 24 (7): 1211-1216. 10.1161/01.ATV.0000131654.90788.f5.PubMed

115.

Mitchell RN, Libby P: Vascular remodeling in transplant vasculopathy. Circ Res. 2007, 100 (7): 967-978. 10.1161/01.RES.0000261982.76892.09.PubMed

116.

Gladue RP, Brown MF, Zwillich SH: CCR1 antagonists: what have we learned from clinical trials. Curr Top Med Chem. 2010, 10 (13): 1268-1277. 10.2174/156802610791561237.PubMed

117.

Zhao Q: Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol. 2010, 88 (1): 41-55. 10.1189/jlb.1009671.PubMed

118.

Khatri P, Roedder S, Kimura N, De Vusser K, Morgan AA, Gong Y, Fischbein MP, Robbins RC, Naesens M, Butte AJ, Sarwal MM: A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J Exp Med. 2013, 210 (11): 2205-2221. 10.1084/jem.20122709.PubMedCentralPubMed

119.

Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW: Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007, 178 (11): 7018-7031.PubMed

120.

Ehrchen J, Steinmuller L, Barczyk K, Tenbrock K, Nacken W, Eisenacher M, Nordhues U, Sorg C, Sunderkotter C, Roth J: Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood. 2007, 109 (3): 1265-1274.PubMed

Title: Macrophages in solid organ transplantation
Authors: Xinguo Jiang
Wen Tian
Yon K Sung
Jin Qian
Mark R Nicolls
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Vascular Cell / Issue 1/2014
Electronic ISSN: 2045-824X
DOI: https://doi.org/10.1186/2045-824X-6-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

In vitropre-vascularisation of tissue-engineered constructs A co-culture perspective

Erratum to: The role of tumor-associated macrophages in tumor vascularization

Lymphangiogenesis and angiogenesis during human fetal pancreas development

Flow-regulated lymphatic vasculature development and signaling

Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro

VEGFR-1 blockade disrupts peri-implantation decidual angiogenesis and macrophage recruitment

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials